By Fineline Cube 
BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), a China-based oncology specialist proposing to change its name to BeOne Medicines Ltd., announced that the U.S. Patent and Trademark Office (USPTO) has rendered a Final Written Decision invalidating all claims of Pharmacyclics LLC’s (Pharmacyclics) U.S. Patent No. 11,672,803 (the ‘803 patent) that were challenged by BeiGene in a post-grant review (PGR) proceeding.
Background of the Challenge
On November 1, 2023, BeiGene filed a PGR petition with the USPTO challenging the validity of certain claims of the ‘803 patent. This action was taken in response to a patent infringement lawsuit that Pharmacyclics had brought against BeiGene concerning Brukinsa (zanubrutinib). On May 1, 2024, the USPTO granted BeiGene’s petition to institute the PGR.
USPTO Decision and Next Steps
The USPTO’s Final Written Decision invalidates all challenged claims of the ‘803 patent. This decision is appealable by Pharmacyclics, setting the stage for potential further legal proceedings.-Fineline Info & Tech